Tacrolimus effect on rosacea

Bamford, Joel T. M. MD
Elliott, Barbara A. PhD
Haller, Irina V. PhD, MS

^aDermatology Section, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota
^bSchool of Medicine Duluth, University of Minnesota, Minnesota
^cDivision of Education and Research, St. Mary's/Duluth Clinic Health System, Duluth, Minnesota.

Correspondence to: Joel T.M. Bamford, MD, Dermatologist St Mary's/Duluth Clinic Health System 400 E Third St, Duluth, MN 55805. E-mail: [email protected].

Funding source: Fujisawa Healthcare, Inc provided a grant for this investigator-initiated study.

Conflict of interest: None identified.

Journal of the American Academy of Dermatology 50(1):p 107-108, January 2004.

Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P < .05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.